MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 4,860,000 shares of its common stock at a price to the public of $35.00 per share. Gross proceeds to Forty Seven from the offering are expected to be $170.1 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock are being offered by Forty Seven. In addition, Forty Seven has granted the underwriters a 30-day option to purchase up to 729,000 of additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 16, 2019, subject to customary closing conditions.
Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock
Dec 12, 2019
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers